Status: Recruiting
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid carcinoma (MTC). The surgical extent of MTC is determined based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, with the main endpoint being 1-month post-surgical calcitonin level.
Participants needed: 50
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUpdated: Feb 26, 2024Locations: 1
Eligibility criteria
Age between 18 and 75 years； [+4]
Have a history of imaging agent allergies; [+3]